Sunita Babbar

Sunita Singh Babbar is a seasoned professional with extensive expertise in toxicology and nonclinical development, currently serving as Vice President at BridgeBio Pharma Inc. since July 2019. Prior roles include Vice President of Nonclinical R&D at Parvus Therapeutics, Senior Director and Director of Nonclinical Research and Development at Revance Therapeutics, and Director of Toxicology at NeurogesX, Inc. Sunita also held positions at NeurogesX, Renovis, Theravance, and Tularik throughout an accomplished career spanning over two decades. Educational qualifications include a Doctorate in Regulatory Science from the University of Southern California, a PhD in Pharmacology from the University of Toledo, an MS in Pharmacology from Idaho State University, and a Bachelor of Pharmacy from the Indian Institute of Technology, Banaras Hindu University.